BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29566171)

  • 1. Genetic analysis of the complement pathway in C3 glomerulopathy.
    Zhao W; Ding Y; Lu J; Zhang T; Chen D; Zhang H; Zeng C; Liu Z; Chen H
    Nephrol Dial Transplant; 2018 Nov; 33(11):1919-1927. PubMed ID: 29566171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
    Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
    Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FHR-5 Serum Levels and
    Garam N; Cserhalmi M; Prohászka Z; Szilágyi Á; Veszeli N; Szabó E; Uzonyi B; Iliás A; Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G; Bajcsi D; Brunner J; Dumfarth A; Cejka D; Flaschberger S; Flögelova H; Haris Á; Hartmann Á; Heilos A; Mueller T; Rusai K; Arbeiter K; Hofer J; Jakab D; Sinkó M; Szigeti E; Bereczki C; Janko V; Kelen K; Reusz GS; Szabó AJ; Klenk N; Kóbor K; Kojc N; Knechtelsdorfer M; Laganovic M; Lungu AC; Meglic A; Rus R; Kersnik Levart T; Macioniene E; Miglinas M; Pawłowska A; Stompór T; Podracka L; Rudnicki M; Mayer G; Rysava R; Reiterova J; Saraga M; Seeman T; Zieg J; Sládková E; Stajic N; Szabó T; Capitanescu A; Stancu S; Tisljar M; Galesic K; Tislér A; Vainumäe I; Windpessl M; Zaoral T; Zlatanova G; Józsi M; Csuka D
    Front Immunol; 2021; 12():720183. PubMed ID: 34566977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P; Noris M; Mele C; Piras R; Valoti E; Bresin E; Curreri M; Mondo E; Zito A; Gamba S; Bettoni S; Murer L; Fremeaux-Bacchi V; Vivarelli M; Emma F; Daina E; Remuzzi G
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
    Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
    Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
    Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
    Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C3 glomerulopathy.
    Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
    Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
    Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2018; 9():2329. PubMed ID: 30487789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C3 glomerulopathy: clinicopathologic features and predictors of outcome.
    Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes.
    Wong EKS; Marchbank KJ; Lomax-Browne H; Pappworth IY; Denton H; Cooke K; Ward S; McLoughlin AC; Richardson G; Wilson V; Harris CL; Morgan BP; Hakobyan S; McAlinden P; Gale DP; Maxwell H; Christian M; Malcomson R; Goodship THJ; Marks SD; Pickering MC; Kavanagh D; Cook HT; Johnson SA;
    Clin J Am Soc Nephrol; 2021 Nov; 16(11):1639-1651. PubMed ID: 34551983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N
    Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
    Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
    Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN.
    Meuleman MS; Vieira-Martins P; El Sissy C; Audard V; Baudouin V; Bertrand D; Bridoux F; Louillet F; Dossier C; Esnault V; Jourde-Chiche N; Karras A; Morin MP; Provot F; Remy P; Ribes D; Rousset-Rouviere C; Servais A; Thervet E; Tricot L; Zaidan M; Wynckel A; Zuber J; Le Quintrec M; Frémeaux-Bacchi V; Chauvet S
    Clin J Am Soc Nephrol; 2023 Nov; 18(11):1435-1445. PubMed ID: 37615951
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Piras R; Breno M; Valoti E; Alberti M; Iatropoulos P; Mele C; Bresin E; Donadelli R; Cuccarolo P; Smith RJH; Benigni A; Remuzzi G; Noris M
    Front Genet; 2021; 12():670727. PubMed ID: 34211499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
    Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
    Pediatr Nephrol; 2024 Apr; ():. PubMed ID: 38662234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.